1 / 16

2014 “Towards an HIV Cure” Symposium Melbourne

2014 “Towards an HIV Cure” Symposium Melbourne. Mirko Paiardini, PhD Yerkes National Primate Research Center Emory University. IL-21 reduces residual inflammation and virus persistence in ART-treated SIV -infected rhesus macaques.

walt
Download Presentation

2014 “Towards an HIV Cure” Symposium Melbourne

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. 2014 “Towards an HIV Cure” SymposiumMelbourne Mirko Paiardini, PhD Yerkes National Primate Research Center Emory University IL-21 reduces residual inflammation and virus persistence in ART-treated SIV-infected rhesus macaques

  2. Implications of residual chronic immune activation in HIV-treated patients non-AIDS-related overall morbidity HIV persistence and replication Residual Inflammation Inflammation in treated HIV disease is: • Higher than expected • Stable over time Currier J.S. AIDS conference 2012 • Strong prognostic importance • Associated with HIV persistence

  3. Contributors to chronic immune activation Paiardini & Muller-Trutwin, Immunol Rev 2013

  4. Laurence et al. Nat Med 2008 IL-17 and IL-22 producing cells are critical for the mucosal immune functions • Important for anti-bacterial/fungal immunity and epithelial integrity • Neutrophil recruitment • Proliferation of GI enterocytes • Production of tight junction proteins • Production of anti-bacterial defensins • If not properly regulated, Th17 pro-inflammatory activity may result in tissue damage

  5. Depletion of intestinal Th17 cells is associated with progression to AIDS • Th17 & Th22 cells are preferentially depleted in pathogenic HIV and SIV infections(Brenchley, 2008; Cecchinato, 2008; Raffatellu, 2008; Campillo-Gimenez, 2010; Li, 2011; Singh, 2012; Klatt, 2012; Kim, 2012) • Th17 cells are preserved in nonpathogenic SIV infection of natural hosts as well as in HIV Elite controllers and LTNP(Brenchley, 2008; Favre, 2009; Brandt, 2011; Salgado, 2011; Ciccone, 2011) • Depletion of Th17 cells is associated with microbial translocation, chronic immune activation, and disease progression (Raffatellu, 2008; Cecchinato, 2008; Gordon, 2010) • Effective CD4 T cell restoration in gut-associated lymphoid tissue of HIV-infected patients is associated with increased Th17 cells (Macal, 2008) • SIV replication in rhesus macaque is limited by the size of the preexisting Th17 cell compartment(Hartigan-O'Connor, 2012) Can we modulate the levels of intestinal Th17 cells in vivo?

  6. Interleukin (IL)-21 functions Rationale • Th17 cell generation is severely impaired in the absence of IL-21 (Nurieva, Nature 2007; Korn, Nature 2007; Yang, Nature 2008) • Plasma levels of IL-21 are reduced in progressive HIV-infection(Iannello A., Viral Immunol 2008; Chevalier M., J Virol 2010; Williams L., J Virol 2010) • IL-21 shows promise in multiple myeloma and renal cell carcinoma trials to improve CD8 and NK cell functions(Davis, Clin Cancer Res 2009; Rasmussen, Br J ClinPharmacol 2010; Steele, Br J Cancer 2012). H. Søndergaard, Tissue Antigens, 2009 Further rationale comes from our previous studies

  7. Study design 16 RMs, 8 ART+IL-21 & 8 ART alone; age/sex matched; 8 A01+, all B08- & B17- cART (PMPA, FTC, Raltegravir, Ritonavir boosted Darunavir) IL-21 IL-21 SIVmac239 (i.v.) 45 47 40 41 39 38 42 34 36 29 19 23 Weeks p.i. 15 12 2 5 9 -2 0 10 Blood Lymph Node Rectal biopsy Rhesus IL-21-Fc-IgG fusion protein; 100ug/kg; s.c. (Francois Villinger, YNPRC) • Does IL-21 improve the partial reconstitution of intestinal Th17 and Th22 cells achieved with ART? • Does it limit residual immune activation/inflammation? • Would this impact on residual viremia and/or size of the latent SIV reservoir?

  8. cART is very effective in suppressing SIV replication in RMs Limit of detection 60 copies/mL; undetectable values plotted at half LOD

  9. Improved homeostasis of Intestinal IL-17 and IL-22 producing cells

  10. IL-21 limits intestinal T cell activation CD4 T cells CD8 T cells

  11. IL-21 limits intestinal T cell proliferation Similar reduction found in CD4 and CD8 T cell activation in blood

  12. IL-21 limits plasma residual viremia d200 d105 on ART: d75 42.8% vs. 25% 85.7% vs. 37.5% % N.D. 28.5% vs. 37.5% Repeated measures analyses: percentages of RMs with undetectable viremia over time is significantly higher in IL-21 treated animals than controls (P=0.03) Limit of detection: 3 copies/mL (Jeff Lifson)

  13. IL-21 reduces cell associated SIV DNA in rectal tissues Jeff Lifson

  14. Conclusions IL-21 administration in ART-treated, SIV-infected RMs: • Is safeand significantly improves reconstitution of intestinal IL-17 and IL-22 producing CD4 T cells • Results in a more rapid and pronounced reduction of residual activation in blood and intestinal T cells • Limits residual viremia in plasma and cell associated SIV-DNA in rectal tissues To explore IL-21 as a potential immunotherapeutic agent for HIV infection

  15. OPEN QUESTIONS – WORK IN PROGRESS • Did IL-21 reduce the levels of soluble markers of inflammation? • Did IL-21 reduce the size of the latent SIV reservoir? • How the achieved results impact on viral rebound following ART interruption? • How the achieved results impact on immune activation following ART interruption?

  16. Acknowledgments Paiardini Lab Luca Micci Emily Ryan Colleen McGary Sara Paganini Zachary Ende* VGTI - Florida Nicolas Chomont CFAR Virology core Thomas Vanderford Benton Lawson Melon Nega DARE Steven Deeks Mike McCune RafickSekaly NIH/NIAID Daniel Douek Jason Brenchley Emory - YNPRC Francois Villinger Guido Silvestri Stephanie Ehnert Christopher Souder Sherrie Jean ART Drugs DariaHazuda(Merck) RomasGeleziunas(Gilead) Guenter Kraus (Janssen) NCI Jeff Lifson Michael Piatak Jake Estes Support – NIH R01-AI084836 R21-AI104278 Case Western Michael Lederman Flow core EVC Barbara Cervasi* * Former lab members

More Related